TOXICITY ASSESSMENT OF CLARITHROMYCIN IN DIABETIC WISTAR RATS TREATED WITH ROSIGLITAZONE

Diabetes is a debilitating metabolic disorder characterized by chronically elevated blood glucose level above the normal range and affects mostly all kind of populations epidemiologically. Objectives: In clinical situations, diabetic patients already on prescription of Rosiglitazone are prone to bacterial infection. To cure such infection Clarithromycin is prescribed particularly in Respiratory Tract Infections. Materials and Methods: Diabetes was induced experimentally in overnight fasted Rats by intraperitoneal injection of Nicotinamide, 15 min prior to intraperitoneal injection of Streptozotocin (60 mg/kg). Nicotinamide (160 mg/kg) was freshly prepared by dissolving in distilled water and Streptozotocin was dissolved in freshly prepared 0.1M Citrate buffer. Since Rosiglitazone and Clarithromycin have found to exert minimal to mild toxicity in animals on these doses, i.e. 80 mg/kg and 400 mg/kg respectively, both these drugs were administered for 14 days to the animals to study the toxicity in diabetic condition. Parameters included for the study includes body weight changes, oral glucose tolerance test, biochemistry, hematology, urine analysis and histopathology. Results: Clarithromycin aggravated hyperglycemia and reduced platelet count in diabetic condition. Further, combination of both Rosiglitazone and Clarithromycin reduced hepatotoxicity and nephrotoxicity in diabetic condition. Clarithromycin and Rosiglitazone combination showed markedly decreased TGL levels indicating Rosiglitazone's additive adverse effect in diabetic as well as non-diabetic condition. Conclusion: Study inform about the two different class of drug which clinically can be used together. Though the combination has shown some promising effects on liver and renal functions in terms of Hepatotoxicity and Nephrotoxicity, concern about the reduced TGL and testicular toxicity cannot be over-looked and thus, further research is warned in this direction.